Moderna Discontinues mRNA Vaccine for Congenital CMV
Moderna has announced the results of a Phase 3 trial evaluating the efficacy of mRNA-1647, its investigational cytomegalovirus (CMV) vaccine.
The study failed to meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years of age).
"The announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV, a leading infectious cause of birth defects," said Stéphane Bancel, Chief Executive Officer of Moderna.
As a result, Moderna will discontinue its congenital CMV clinical development program.
Author's summary: Moderna stops CMV vaccine development.